News Feature | June 12, 2014

Beactica And Medivir Enter Drug Discovery Partnership

By Estel Grace Masangkay


Swedish fragment-based drug discovery company Beactica and Medivir AB announced that the companies have entered into collaboration.

Under the terms of the agreement, Beactica will leverage its proprietary discovery platform to determine new hits against a disease-relevant protease of therapeutic interest specified by Medivir. “We are pleased that Medivir has selected Beactica to advance one of their prioritized discovery programs. Medivir is at a very exciting point in their development and we are looking forward to tackle this challenging project together with their team of innovative scientists,” said Beactica CEO, Dr. Per Källblad.

Dr. Richard Bethell, Medivir's EVP of discovery research, said that the company is looking forward to the start of its collaboration with Beactica and using its fragment-based lead discovery technology to search for hits active against one of Medivir’s early discovery targets.

No financial terms of the agreement were disclosed by either company.

One of Beactica’s latest collaborations was with Boehringer Ingelheim, which was expanded last October 2013 to discover new and selective hits against oncology-related kinases.

Founded in 2006 based on research from Uppsala University, Beactica offers expertise and services in surface plasmon resonance (SPR) biosensor-based small molecule interaction analysis. The company also uses its proprietary Sprint platform to build partnerships for fragment-based lead generation. Beactica focuses on investigating molecule interaction to generate new and mechanistically defined therapeutics.

Research-based pharmaceutical company Medivir is focused on developing treatments against infectious diseases. The company is developing its infectious disease research and development portfolio. Medivir’s leading asset is simprevir, a new protease inhibitor co-developed with Janssen R&D Ireland for the treatment of hepatitis C. The company recently announced the coming launch of Olysio in all Nordic countries for the treatment of adults with hepatitis C genotype 1 and 4 infection.